15.72  0.27 (1.75%)		04-26 16:00
Open: 15.33 High: 16 Volume: 200,660		Pre. Close: 15.45 Low: 15.125 Market Cap: 401(M)

Short term
Mid term
Targets	6-month :	24.48	1-year :	28.72
Resists	First :	20.96	Second :	24.59
Pivot price	18.39
Supports	First :	15.09	Second :	12.55
MAs	MA(5) :	15.76	MA(20) :	19
	MA(100) :	6.85	MA(250) :	4.28
MACD	MACD :	1	Signal :	2.1
%K %D	K(14,3) :	6.7	D(3) :	5.9
RSI	RSI(14): 49.3
52-week	High :	24.59	Low :	2

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ LENZ ] has closed above bottom band by 22.2%. Bollinger Bands are 98.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	16.02 - 16.11	16.11 - 16.19
Low:	14.89 - 15.01	15.01 - 15.11
Close:	15.55 - 15.72	15.72 - 15.88

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Mon, 15 Apr 2024
William Blair rates LENZ Therapeutics stock positively on aceclidine's potential in presbyopia By Investing.com - Investing.com

Wed, 10 Apr 2024
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape ... - Markets Insider

Wed, 03 Apr 2024
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study - Marketscreener.com

Wed, 03 Apr 2024
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials - Business Wire

Wed, 03 Apr 2024
Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study - Yahoo Finance

Wed, 03 Apr 2024
Lenz Therapeutics' eye drop helps improve vision in late-stage study - Reuters

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	26 (M)
Shares Float	10 (M)
Held by Insiders	5.6 (%)
Held by Institutions	69.9 (%)
Shares Short	86 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-77.2 %
Return on Equity (ttm)	-157.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.84
Qtrly Earnings Growth	0 %
Operating Cash Flow	-60 (M)
Levered Free Cash Flow	-34 (M)

PE Ratio	0
PEG Ratio	-0.4
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-6.65

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.